<DOC>
	<DOCNO>NCT00116298</DOCNO>
	<brief_summary>The purpose study compare long-term safety tolerability stavudine ( d4T ) extend release ( ER ) versus conventional ( immediate release [ IR ] ) formulation , combination lamivudine ( 3TC ) efavirenz ( EFV ) subject complete Bristol-Myers Squibb ( BMS ) study AI455-096 AI455-099 .</brief_summary>
	<brief_title>Rollover Study Zerit ( Stavudine ) ER Studies ( -096 , -099 )</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Stavudine</mesh_term>
	<mesh_term>Efavirenz</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<criteria>Completed d4T study AI455096 AI455099 Have demonstrate compliance study medication treatment visit Provide write informed consent Agree use barrier method birth control ( condom ) study Have negative pregnancy test within 72 hour prior start study medication Are pregnant breastfeed Need take certain medication systemic myelosuppressive , neurotoxic , pancreatotoxic , hepatotoxic cytotoxic potential Have active alcohol substance abuse may prevent compliance increase risk develop pancreatitis Have certain condition prior treatment might interfere study continuation Need take certain medication take EFV</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>Antivirals</keyword>
	<keyword>HIV</keyword>
</DOC>